Global Hemp Group Welcomes Mathieu Couillard and the Continuing Engagement of Twilight Capital on Its Advisory Board

2023-02-17
高管变更
Vancouver, British Columbia--(News - February 17, 2023) - GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) ("GHG" or the "Company") is pleased to announce the addition of Mathieu Couillard and the continuing engagement of Twilight Capital on its Advisory Board. The Company welcomes Mathieu Couillard as its Business Development and Capital Markets Advisor. Mr. Couillard served as Managing Director of investment banking at Haywood Securities, leading the Special Situations team from 2016 to 2022. Mr. Couillard is an experienced investment banker who has extensive experience in the cannabis space. He has participated in over $1 Billion in capital raises for cannabis companies from start-ups to some of the largest players in the industry. He is the architect of numerous mergers and acquisitions. Prior to joining Haywood Securities Mr. Couillard was part of the Risk Management Solutions group specializing in the sales and structuring of derivative products at National Bank of Canada in Toronto. From 2006 to 2014, Mr. Couillard was part of National Bank's investment banking group in Montreal. Mr. Couillard is a Fellow of the Society of Actuaries. The Company also announces the continuing engagement of Twilight Capital as Special Advisor/Capital Markets. Twilight Capital is an M&A and Capital Markets Advisory consulting firm headed by Nikolas Perrault. Mr. Perrault is a Chartered Financial Analyst with significant experience in the technology, financial, and natural resources industries. He provides strategic advice to select clients on a global scale. Mr. Perrault obtained his Chartered Financial Analyst designation in 1997, and spent the first 15 years of his career with Canada's large institutions like National Bank, Merrill Lynch, CIBC, and Scotia Capital. His focus throughout his career has been on small to medium-cap companies worldwide which allowed him to develop an extensive international network. The Company also announces that it has granted incentive stock options to Directors, Officers and Consultants to acquire up to an aggregate of 17,900,000 common shares in the capital stock of the Company. The options vest immediately, are exercisable at a price of $0.05 per share for a period of five years from the date of the grant. Subscribe to the GHG YouTube Channel: Like us on Facebook: Follow us on Instagram: Follow us on Twitter: Connect with us on LinkedIn: About Global Hemp Group Inc. Global Hemp Group Inc. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) is focused on executing a multi-phased strategy to become a leader in the industrial hemp industry. To further support and innovate, GHG has established a R&D Division to actively pursue the development of Intellectual Property that can be patented for implementation at its projects and beyond. The Division is led by Prof. Víctor M. Castaño, Ph.D. who specializes in the areas of applied science and technology. The R&D team will initially focus on development of Environmentally Friendly Construction Materials, Nanofertilizers and Enhanced Extraction from Hemp. GHG has expanded its scope of business into natural biologic therapeutics having acquired the exclusive North America licensing of patents and IP from Apollon Formularies plc, a UK-based international pharmaceutical company developing cancer treatments from natural biologics, including medical cannabis, functional mushrooms, psychedelic mushrooms and combinations of these compounds, which to date have shown successful independent, third-party results in pre-clinical testing. Apollon utilizes an artificial intelligence-based drug discovery platform. GHG will look to begin sub-licensing this IP throughout Canada, the United States and Mexico where legally permitted to do so. For Further Information Contact Global Hemp Group Curt Huber, President Tel: 778-726-2900 info@globalhempgroup.com Cautionary Note Regarding Forward-Looking Statements Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Global Hemp Group Inc., including, but not limited to, the impact of general economic conditions, industry conditions, volatility of commodity prices, currency fluctuations, dependence upon regulatory approvals, the availability of future financing and exploration risk, and the legality of cannabis and hemp. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Except as required by law, Global Hemp Group Inc. disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise. The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
-
靶点
-
药物
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。